Seminars in Oncology
Volume 35, Issue 1 , Pages 64-71, February 2008

The Medical Treatment of Inflammatory Breast Cancer

  • Shaheenah Dawood

      Affiliations

    • Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates.
  • ,
  • Naoto T. Ueno

      Affiliations

    • The Morgan Welch Inflammatory Breast Cancer Research and Clinic–Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
    • Department of Stem Cell Translation and Cellular Therapy, Breast Cancer Translational Research Laboratory, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • ,
  • Massimo Cristofanilli

      Affiliations

    • The Morgan Welch Inflammatory Breast Cancer Research and Clinic–Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
    • Corresponding Author InformationAddress correspondence to Massimo Cristofanilli, MD, Breast Medical Oncology Department, Unit 1354, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030.

The multidisciplinary management of inflammatory breast cancer (IBC) includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and, in hormone receptor–positive disease, hormonal therapy. The use of induction chemotherapy with anthracyclines and taxanes somewhat improved the prognosis and local control of patients with IBC compared to local modalities alone. Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00237-0

doi:10.1053/j.seminoncol.2007.11.012

Seminars in Oncology
Volume 35, Issue 1 , Pages 64-71, February 2008